Main Product: DNA Stool Test
GLC’s main product is a non-invasive stool DNA test for colon cancer screening. This test involves three main steps:
- Stool Collection and Transportation to Clinical Lab
- DNA and Biomarker Extraction from Stool Sample
- Biomarker Analysis
First patients collect stool at home using GLC developed stool preservation kits. These kits are mailed or dropped off at either independent or hospital-affiliated labs.
Next, using a patented DNA extraction kit developed by GLC, labs will extract DNA from the stool samples.
Finally, labs use GLC’s biomarkers to identify if a patient has colon cancer or not.
Pipeline Product: Liquid Biopsy
GLC has leveraged its DNA extraction technologies to develop assays for liquid biopsy of cancer, a blood-based DNA test.
Liquid biopsy is emerging as a new approach to early cancer detection and management of cancer treatment. There is great excitement in the area because blood tests are simple and convenient.
However, like stool DNA tests, liquid biopsy suffers from poor sensitivity when used to detect early stages of cancer. This is because there are much fewer tumor-derived DNA molecules in blood than organs directly affected by cancers. This scarcity of tumor-derived DNA requires more efficient DNA extraction methods.
Although GLC’s focus is on stool DNA tests, GLC was able to extract 8x more tumor-derived DNA from blood than current technologies. Thus, we see massive opportunity in this space.